IMRA News and Press, IMARA Inc. From 02/21/22

There are many ways to find the best penny stocks to buy , including hunting for chart set-ups and looking for unusual trading activity. Others focus their strategy around finding top stocks under $1 or even below $0.50 that might be considered a good long shot investment opportunit...

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ba...

In this article, we take a closer look at 5 penny stocks gaining ground after releasing big news today. Thanks to even more stock market uncertainty, retail traders have turned attention to daily trends, and rightfully so. The last week has seen markets pop and drop significant percentages ...

Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched PDE9 expression for targeted approach to a heterogeneous disease ...

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today an...

Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261 activation of Nrf2 increases HbF and F-cells, reduces VOCs and reduces markers of a...

BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today an...

Primary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation No change to conduct or size of trial planned; Ardent trial remains on track for interim analysis of VOC rates in first quarter of 2022 BOSTON, Nov....

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In order to find penny stocks that have a strong likelihood of booking profits within the next six weeks, investors are going to have to accept an extra measure of risk. That’s because there’s inherent risk i...

Imara (NASDAQ:IMRA) announces data from a pre-specified interim analysis from its Forte Phase 2b clinical trial of tovinontrine (IMR-687) in transfusion-dependent subjects (TDT) with beta-thalassemia. Shares advance 4.5% premarket. “We are encouraged by the positive trend for...